| Literature DB >> 35406160 |
Najla M Salkho1,2, Nahid S Awad1, William G Pitt3, Ghaleb A Husseini1,2.
Abstract
Chemotherapeutic drugs are highly effective in treating cancer. However, the side effects associated with this treatment lower the quality of life of cancer patients. Smart nanocarriers are able to encapsulate these drugs to deliver them to tumors while reducing their contact with the healthy cells and the subsequent side effects. Upon reaching their target, the release of the encapsulated drugs should be carefully controlled to achieve therapeutic levels at the required time. Light is one of the promising triggering mechanisms used as external stimuli to trigger drug release from the light-responsive nanocarriers. Photo-induced drug release can be achieved at a wide range of wavelengths: UV, visible, and NIR depending on many factors. In this review, photo-induced release mechanisms were summarized, focusing on liposomes and micelles. In general, light-triggering mechanisms are based on one of the following: changing the hydrophobicity of a nanocarrier constituent(s) to make it more soluble, introducing local defects within a nanocarrier (by conformational transformation or photo-cleavage of its lipids/polymers chains) to make it more porous or concentrating heat for thermo-sensitive nanocarriers to release their payload. Several research studies were also presented to explore the potentials and limitations of this promising drug release triggering mechanism.Entities:
Keywords: chemotherapy; light; nanocarriers; photoresponsive; triggering release
Year: 2022 PMID: 35406160 PMCID: PMC9003562 DOI: 10.3390/polym14071286
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Advantages and challenges of triggering stimuli used in drug delivery.
| Stimulus | Advantage | Challenge | Reference |
|---|---|---|---|
| pH |
Distinct pH in tumor (pH = 6.5–7.2) compared to blood (pH = 7.35–7.45) and other organs. Intrinsically safe. |
Slow kinetics for drug release. Endogenous triggers are difficult to control (i.e., pH variation in tumor from one patient to another). A narrow range of pH variation poses a stability issue for nanocarriers. | [ |
| Ultrasound (US) |
Non-ionizing safe radiation with deep penetration into tissue. Enhanced cell permeability and drug diffusion due to sonoporation. Potential for image-guided treatment. Easy to control. |
US-responsive medium (gas/PFC) is required. Possible tissue damage by heat for high-intensity US. Possible tissue damage by irreversible pore formation in cell membranes. | [ |
| Light |
Potential to be highly focused more than other stimuli (e.g., ultrasound and magnetic field). A wide range of operating wavelengths: UV, visible, and NIR. |
Low penetration into tissue by UV and visible light. NIR penetrates tissue deeper but with lower energy which may not induce phototriggering from nanocarriers. The energy released from nanocarriers that require high light dosage can thermally damage tissues. | [ |
| Magnetic Field |
Safe with high precision. Tissues with accumulated magnetic nanoparticles will only be affected while nearby tissues remain transparent to the magnetic field. Potential for magnetically-guided drug targeting through contrast agents. Drug release from thermo-sensitive nanocarriers by hyperthermia via an alternating magnetic field. |
Potential toxicity from metals (e.g., ROS from iron oxide decomposition). Expensive and complex equipment set-up that requires high expertise. A high external magnetic field is required to induce magnetism, especially in deep tissues. Difficulty to focus alternating magnetic field. | [ |
| Hyperthermia |
Enhanced tumor permeability. Reduced hypoxic conditions and increased blood flow and drug delivery. Synergistic effect. Apoptosis of cancer cells is sensitive to hyperthermia. Effective in transdermal administration. |
Difficult to spatially control hyperthermia (~40–42 °C) at the tumor. Risk of superficial tissue damage by heat. | [ |
Figure 1Photo-induced mechanisms used in triggering drug release from nanocarriers. (a) Photo-isomerization; (b) Photo-cleavage; (c) SPR of Gold NPs for thermo-sensitive nanocarriers, gold NPs can be on the surface or inside.
Figure 2Azobenzene photo-isomerization.
Figure 3Photo-isomerization of Spiropyran and Merocyanine.
Figure 4Photo-oxidation of plasmalogen at the vinyl ether linkage mediated by singlet oxygen.
Figure 5Photo-cleavable o-nitrobenzyl ester irradiated with UV light.
Figure 6Surface plasmon resonance.
Figure 7Surface plasmon resonance for different sizes of gold nanoparticles. Reprinted with permission from [38]. Copyright 1999 American Chemical Society.
Figure 8Hydrophobic to hydrophilic change of DNQ after Wolff rearrangement induced by UV/NIR light in buffered water.
Figure 9(a) Preparation of nanogel particles through micelle formation at T > LCST, followed by crosslinking of coumarin by UV irradiation at λ1 > 310 nm. De-crosslinking was achieved by irradiation at λ2 < 260 nm; (b) Reversible photo-crosslinking of di-block copolymer PEO-b-P(MEOMA-co-CMA). Reprinted with permission from [43]. Copyright 2009 American Chemical Society.
Photo-triggered drug release in-vitro studies.
| Mechanism | Nanocarrier | Loaded/Conjugated Drug | Active Moiety | Light Wavelength | Reference |
|---|---|---|---|---|---|
| photo-isomerization | Liposome | Sulforhodamine B | Monoacylated azobenzene amphiphile | 350 nm | [ |
| Micelle | Pyrene | Spiropyran | 254 nm | [ | |
| Micelle | Doxorubicin | Spiropyran | 365 nm | [ | |
| Micelle | Nile Red | Donor–acceptor Stenhouse adducts (DASA) | Visible light | [ | |
| Photo-cleavage | Liposome | Co-loaded with doxorubicin hydrochloride + ZnPcRLA | ZnPcRLA | 685 nm | [ |
| Liposome | Basic orange 14 | Cationic amphiphilic phthalocyanine | 665 nm | [ | |
| Liposome | Calcein | NVOC-DOPE | λ > 300 nm (UV) | [ | |
| Liposome | 5(6)-carboxyfluorescein | Hydrophobically modified poly(vinyl alcohol)-epoxypropoxy coumarin | 254 nm | [ | |
| Micelle | Doxorubicin | 365 nm | [ | ||
| Surface plasmon resonance absorption | Gold nanoparticles | Doxorubicin | Gold nanoparticles | 660 nm | [ |
| Liposome | Doxorubicin | Gold nanoparticles | 660 nm | [ | |
| Liposome | Calcein | Gold nanoparticles | 656 nm850 nm | [ |
Photosensitizer-loaded nanomedicine in-vivo studies.
| Photosensitizer | Nanocarrier | Tumor Model | Reference |
|---|---|---|---|
| Foslip® (m-THPC) | Liposome | HT29 (human-derived colon adenocarcinoma cell line) | [ |
| 143B (human-derived osteosarcoma cell line) | [ | ||
| CAL-33 (human-derived tongue squamous carcinoma cell line) | [ | ||
| Fospeg® (m-THPC) | Liposome | HT29 (human-derived colon adenocarcinoma cells) | [ |
| 143B (human-derived osteosarcoma cell line) | [ | ||
| MC28 (methylcholanthrene-induced fibrosarcoma cell line) | [ | ||
| Foscan | Lipidots nanoemulsion (Lecithin-PEG) | CAL-33 (human-derived tongue squamous carcinoma cell line) | [ |
| Polymeric micelles (P(CL-TMC-Bz)-PEG) and (Bz-PCL-PEG) | A431 (human-derived squamous cell line) | [ | |
| Visudyne® (verteporfin) | Liposomes | Meth-A sarcoma | [ |
| A431 (human-derived squamous cell line) | [ |
Figure 10Self-illuminating quantum dots (QDs) interacting with photosensitizer-loaded micelle through BRET. Adapted from [66].